Iron Every Other Day Worked Just as Well: New Trial
October 26, 2026Ashwagandha Doubled Strength Gains in a 90-Day Trial
October 28, 2026Quick Summary
A two-year trial in Denmark just gave vitamin K2 its best result yet. In nearly 400 older adults whose heart arteries were already heavily calcified, a daily combo of vitamin K2 and vitamin D3 slowed further calcification by 21% compared with placebo. The catch? Calcification still got worse in both groups — just more slowly in the vitamin group — and the study was too small to show whether that translates into fewer heart attacks.
Picture calcium slowly hardening inside your heart’s arteries, like limescale in a kettle. Now picture a vitamin slowing that buildup by a fifth. That’s what Danish researchers just reported — in the largest trial ever to test this vitamin pair on hardening arteries.
| Topic | What the research shows |
|---|---|
| The trial | DANCODE: a double-blind, placebo-controlled trial at three Danish hospitals, published in Circulation |
| Who took part | 398 adults, median age 71, all with severe coronary artery calcification (a calcium score of 400 or higher) |
| What they took | 720 micrograms of vitamin K2 (MK-7) plus 25 micrograms (1,000 IU) of vitamin D3, every day for 24 months |
| Headline result | Artery calcification progressed 21% more slowly in the vitamin group than in the placebo group |
| The big caveat | The study measured artery scans, not heart attacks — it can’t prove the vitamins prevent cardiac events |
What the researchers actually tested
Coronary artery calcification — CAC for short — is calcium deposited in the walls of the arteries that feed your heart. Doctors measure it with a CT scan and score it in Agatston units. A score of 400 or more counts as severe, and higher scores track with higher cardiovascular risk. The DANCODE volunteers were well past that line: their median starting score was 903, and 44% scored 1,000 or above.
Everyone in the trial was already getting standard heart care — nearly 87% were on a statin. Half got the vitamin combo, half a placebo, and neither the participants nor the researchers knew who got what. Arteries were scanned at the start, after one year, and after two years.
The idea behind the combo is a protein called matrix Gla protein, or MGP — a traffic cop for calcium. When MGP is switched on, it helps keep calcium in bones and out of artery walls. Vitamin K is needed to switch MGP on, and vitamin D boosts how much MGP the body makes. The theory is neat. Until now, though, human trials testing it had produced mixed results at best.
The 21% result — and the fine print
After two years, calcification had increased in both groups — that’s normal for people with severe calcification. But it increased a lot less in the vitamin group.
| Group | Average increase in calcium score |
|---|---|
| Vitamin K2 + D3 | 196 Agatston units |
| Placebo | 248 Agatston units |
| Difference | 52 units less progression — a 21% relative reduction |
The benefit showed up whether volunteers started with moderate calcification (scores of 400–999, where progression was 39 units lower) or very high calcification (scores of 1,000-plus, where it was 70 units lower), and it held for both men and women. In a smaller imaging subgroup of 143 people, the vitamins slowed the growth of calcified plaque without increasing softer, non-calcified plaque.
A blood marker backed up the mechanism: levels of inactive MGP fell sharply in the vitamin group (383 versus 591 pmol/L on placebo), suggesting the supplements really did switch the calcium-traffic-cop protein on.
Now the fine print, and it matters. First, this was a combination trial, so nobody can say how much of the effect came from K2, D3, or the pair together. Second, the MK-7 dose — 720 micrograms a day — is a study dose, higher than what’s typically found in store-bought K2 supplements, so these results don’t automatically apply to a lower-dose product off the shelf. Third, and most important: only 2 people in the vitamin group and 3 in the placebo group had a major cardiovascular event during the trial. The study was never designed to detect differences in heart attacks or strokes, so it cannot claim the vitamins prevent them.
Why this trial stands out anyway
Supplement trials disappoint far more often than they deliver, and vitamin D alone has flopped in trial after trial for heart protection. What makes DANCODE different is that it tested a specific mechanism — the MGP pathway — in exactly the people most likely to show a change, at a dose high enough to engage that pathway, for long enough to see it on a scan. The researchers didn’t claim a miracle. They showed a measurable slowing of a validated risk marker, with a matching change in the blood marker that explains it. That’s a stronger package than most vitamin headlines offer — and a reminder that this isn’t about “cleaning” arteries. Nothing in this trial reversed calcification or dissolved plaque.
What is vitamin K2 and how is it supposed to work?
Vitamin K is a family of fat-soluble vitamins, not a single compound. Vitamin K1 (phylloquinone) comes mostly from green leafy vegetables like spinach and kale. Vitamin K2 is a group of compounds called menaquinones, labelled MK-4 through MK-13. The two on most labels are MK-4 and MK-7.
MK-7 is the form used in the DANCODE trial. It comes from bacterial fermentation — the richest food source is natto, a traditional Japanese fermented soybean dish — and smaller amounts show up in aged cheeses, egg yolks, and meats. Because vitamin K is fat-soluble, it’s absorbed best when taken with a meal containing some fat.
Once in the body, vitamin K helps switch on several proteins. Two matter most here: osteocalcin, involved in bone mineralization, and MGP, the protein that may help restrain calcium deposits in blood vessel walls. When MGP is fully switched on, calcium is more likely to end up in bone, where it belongs, and less likely to settle in arteries.
What are the side effects of vitamin K2?
Vitamin K has a reassuring safety profile: health authorities have never set a tolerable upper intake level for it because no adverse effects from food or supplements have been reported in humans. That doesn’t mean unlimited doses are wise — it means toxicity from vitamin K is not a known problem.
But there is one interaction that genuinely matters. Vitamin K can interfere with blood-thinning drugs like warfarin, which work by blocking vitamin K’s action. If you take warfarin or a similar anticoagulant, you need to keep your vitamin K intake consistent — a sudden jump from a new supplement can weaken the drug’s effect. Talk to your doctor or pharmacist before adding a K2 supplement.
A few other medicines can lower vitamin K levels, including certain antibiotics, bile-acid sequestrants used for cholesterol, and the weight-loss drug orlistat. People with malabsorption conditions such as celiac disease or cystic fibrosis, or who have had bariatric surgery, may also absorb vitamin K poorly.
How much vitamin K2 should you take?
There’s no official recommended daily amount specifically for K2. For vitamin K overall, the adequate intake for adults is 120 micrograms a day for men and 90 for women — but that’s based mostly on K1 from food, not a target for K2 supplements.
The DANCODE trial used 720 micrograms of MK-7 daily, and that’s a research dose, not a recommendation. No one has established an optimal K2 dose or shown that more is better. If you decide to try K2, the right dose is still an open question — and anyone taking a blood thinner should treat that question as one for their clinician, not a label.
What should you look for on the label?
First, the form: the trial evidence behind K2 and arteries is for MK-7, not MK-4, so if arterial health is your reason for looking, MK-7 is the form the research actually used. Second, in Canada, check for a valid Natural Product Number (NPN) on the label — that tells you Health Canada has licensed the product and reviewed it for safety and quality. Third, look for third-party testing and a fully disclosed dose, not a proprietary blend that hides how much MK-7 you’re actually getting. And remember the trial paired K2 with vitamin D3, so a combined D3-plus-K2 product mirrors the study design more closely than K2 alone.
References
- Hasific, S., Øvrehus, K. A., Mejldal, A., et al. (2026). Vitamin K2 and D3 supplementation in patients with severe coronary artery calcification: The DANCODE trial. Circulation, 154(17), 1656–1665. https://doi.org/10.1161/CIRCULATIONAHA.126.082363
- National Institutes of Health, Office of Dietary Supplements. (n.d.). Vitamin K: Health professional fact sheet. https://ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/
This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.
